Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells

Interferon regulatory factor�3 mediates Poly(I:C)-induced innate immune response and apoptosis in non‑small cell lung cancer

(2018) Liang Yi et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

(2017) Frank (Xiaohu) Fan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers

(2017) Chengcheng Zhang et al.   MOLECULAR THERAPY

FDA approves first CAR T therapy

(2017) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy

(2017) Lisa Rosenbaum   NEW ENGLAND JOURNAL OF MEDICINE

Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhighneutrophils

(2017) Camilla Engblom et al.   SCIENCE

FDA Approves Second CAR T-cell Therapy

(2017)   Cancer Discovery

A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy

(2017) Yohei Takeda et al.   Cell Reports

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

(2017) Irene Scarfò et al.   Journal for ImmunoTherapy of Cancer

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

(2016) Elise A. Chong et al.   BLOOD

Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway

(2016) Hiroaki Shime et al.   CELL DEATH AND DIFFERENTIATION

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas

(2016) A. H. Long et al.   Cancer Immunology Research

Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer

(2015) Parvin Forghani et al.   BREAST CANCER RESEARCH AND TREATMENT

Type IIFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human

(2015) Lisa Andzinski et al.   INTERNATIONAL JOURNAL OF CANCER

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses

(2014) Xuanming Yang et al.   CANCER CELL

Targeting the Effector Site with IFN-  -Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors

(2014) A. J. Currie et al.   JOURNAL OF IMMUNOLOGY

Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors

(2012) H. Shime et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anticancer function of polyinosinic-polycytidylic acid

(2011) Yu-sheng Cheng et al.   CANCER BIOLOGY & THERAPY

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma

(2010) C. Xuan et al.   BLOOD

Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model

(2010) Jadwiga Jablonska et al.   JOURNAL OF CLINICAL INVESTIGATION

Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon–independent apoptosis in human melanoma cells

(2009) Robert Besch et al.   JOURNAL OF CLINICAL INVESTIGATION

Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study

(2009) Richard H. Ko et al.   JOURNAL OF CLINICAL ONCOLOGY

The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice

(2008) Mohamed L. Salem et al.   VACCINE